<b>Current options for the treatment of<i>Helicobacter pylori</i></b>

Georgopoulos, Sotirios D.; Papastergiou, Vasilios; Karatapanis, Stylianos

doi:10.1517/14656566.2013.763926

Cited by 56 publications

(50 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Socioeconomically, H. pylori infection increases the risk of malignancy and the expense of H. pylori-associated morbidity [9] . H. pylori infection has also been related to non-digestive conditions such as ischemic heart disease, stroke, Alzheimer's disease, Parkinson's disease, and iron deficient anemia [4,10] . In other report, some patients with gastritis resolved H. pylori infection without using antibiotic treatment [11] .…”

Section: Introductionmentioning

confidence: 99%

Antibiotic treatment forHelicobacter pylori: Is the end coming?

Kim

Choi

Chung

2015

WJGPT

View full text Add to dashboard Cite

Infection with the Gram-negative pathogen Helicobacter pylori (H. pylori ) has been associated with gastroduodenal disease and the importance of H. pylori eradication is underscored by its designation as a group I carcinogen. The standard triple therapy consists of a proton pump inhibitor, amoxicillin and clarithromycin, although many other regimens are used, including quadruple, sequential and concomitant therapy regimens supplemented with metronidazole, clarithromycin and levofloxacin. Despite these efforts, current therapeutic regimens lack efficacy in eradication due to antibiotic resistance, drug compliance and antibiotic degradation by the acidic stomach environment. Core tip: This article reviews the recent literature describing antibiotic resistance and trends in Helicobacter pylori (H. pylori ) treatment. As there is no effective conventional therapy, new treatments are being developed and bismuth quadruple, sequential, concomitant therapies are recommended as a first-line regimen in regions with high levels of clarithromycin resistance. Quinolones have also been used for H. pylori treatment, although the cure rate has gradually reduced with this approach. New therapeutic directions include probiotic supplementation, tailored therapy, novel agents, and nanotechnology.

show abstract

Section: Introductionmentioning

confidence: 99%

Antibiotic treatment forHelicobacter pylori: Is the end coming?

Kim

Choi

Chung

2015

WJGPT

View full text Add to dashboard Cite

show abstract

“…Helicobacter pylori is thought to be involved in the pathogenesis of gastritis, peptic ulcer disease, gastric cancer, mucosa-associated lymphoid tissue lymphoma and various extra-gastrointestinal manifestations (1) (2) (3) . Unfortunately, emerging bacterial resistance causes treatment problems, leading to a search for new treatment regimens.…”

mentioning

confidence: 99%

Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey

Caliskan

Tokman

Erzın

et al. 2015

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction: Antibiotic resistance is the main factor that affects the effi cacy of current therapeutic regimens against Helicobacter pylori. This study aimed to determine the rates of resistance to effi cacy clarithromycin, amoxicillin, tetracycline, levofl oxacin and metronidazole among H. pylori strains isolated from Turkish patients with dyspepsia. Methods: H. pylori was cultured from corpus and antrum biopsies that were collected from patients with dyspeptic symptoms, and the antimicrobial susceptibility of H. pylori was determined using the E-test (clarithromycin, amoxicillin, tetracycline, metronidazole and levofl oxacin) according to the EUCAST breakpoints. Point mutations in the 23S rRNA gene of clarithromycin-resistant strains were investigated using realtime PCR. Results: A total of 98 H. pylori strains were isolated, all of which were susceptible to amoxicillin and tetracycline. Of these strains, 36.7% (36/98) were resistant to clarithromycin, 35.5% (34/98) were resistant to metronidazole, and 29.5% (29/98) were resistant to levofl oxacin. Multiple resistance was detected in 19.3% of the isolates. The A2143G and A2144G point mutations in the 23S rRNA-encoding gene were found in all 36 (100%) of the clarithromycin-resistant strains. Additionally, the levofl oxacin MIC values increased to 32 mg/L in our H. pylori strains. Finally, among the clarithromycin-resistant strains, 27.2% were resistant to levofl oxacin, and 45.4% were resistant to metronidazole. Conclusions: We conclude that treatment failure after clarithromycin-or levofl oxacinbased triple therapy is not surprising and that metronidazole is not a reliable agent for the eradication of H. pylori infection in Turkey.

show abstract

“…Ayrıca son dönemde yapılan araştırmalar sonucunda HP enfeksiyonunun, hematolojik, nörolojik ve kardiyovasküler hastalıklar gibi gastrointestinal sistem dışı hastalıklarla da ilişkisi olduğu tespit görülmüştür (18).…”

Section: Discussionunclassified

Dispepsi Şikâyeti ile Başvuran Hastalarda Helikobakter Pilori Pozitifliği Açısından C-14 Üre Nefes Testi ile Endoskopinin Karşılaştırılması

Korkut

Kilit

Işık

et al. 2016

Aile Hekimliği Ve Palyatif Bakım

View full text Add to dashboard Cite

Hastanesine dispeptik şikayetlerle başvuran ve HP enfeksiyonu şüphesi ile C-14 ÜNT yapılan 183 hasta dahil edildi. Hastaların kayıtları geriye dönük olarak incelendi. Bulgular: Çalışmaya yaş aralığı 7-71 arasında değişen 183 hasta alındı. Yaş ortalaması 31±15 yıl idi ve hastaların 129'u kadın (%7), 54'ü erkekti (%30). C-14 ÜNT sonucunda hastaların 77'sinde (%42) HP negatif, 2'sinde (%1) HP şüpheli, 104 hastada (%57) HP pozitifti. HP negatif ve HP pozitif gruplar arasında yaş ve cinsiyet bakımından anlamlı fark yoktu. C-14 ÜNT ile üst gastrointestinal sistem endoskopi sonuçları karşılaştırıldığında, iki yöntem arasında HP pozitifliğinin tespiti açısından fark olmadığı tespit edildi (p>0.05). Sonuç: C-14 ÜNT, HP tanısında kullanılabilecek güvenilir, noninvaziv ve pratik bir testtir.

show abstract

Current options for the treatment ofHelicobacter pylori

Cited by 56 publications

References 95 publications

Antibiotic treatment forHelicobacter pylori: Is the end coming?

Antibiotic treatment forHelicobacter pylori: Is the end coming?

Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey

Dispepsi Şikâyeti ile Başvuran Hastalarda Helikobakter Pilori Pozitifliği Açısından C-14 Üre Nefes Testi ile Endoskopinin Karşılaştırılması

Contact Info

Product

Resources

About